Women's Health Therapeutics Market Poised For Growth: Innovation, Investment And Global Impact

(MENAFN- PR Newswire)

"BCC Research presents an in-depth analysis of how innovations, market dynamics, regional trends and ESG strategies are shaping the $81.2 billion women's health therapeutics market."

BOSTON, May 8, 2025 /PRNewswire/ -- As global awareness of gender-specific medicine continues to rise, the women's health therapeutics market is entering a pivotal era of innovation and investment. Leading pharmaceutical players-such as Pfizer Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.-are accelerating the development of targeted therapies to address conditions like breast cancer, menopause, PCOS and endometriosis.

According to the report, growing emphasis on personalized medicine and biologics is reshaping corporate strategies, especially as North America leads global expansion and emerging technologies unlock new care models. While the market is projected to grow at a CAGR of 5.7% from 2024 to 2029 , stakeholders must navigate regulatory hurdles and rising treatment costs to capture long-term value. This shift marks a profound transformation in how biotech investors, manufacturers, and healthcare providers approach women's health-transitioning it from underserved to a global priority.

Market Overview: Key Insights and Forecast
BCC Research's latest report on Women's Health Therapeutics: Technologies and Global Markets provides a comprehensive breakdown of market trends, investment dynamics, and therapeutic pipelines. The global market is expected to grow from $61.5 billion in 2024 to $81.2 billion by 2029 , reflecting a shift toward biologics, hormonal therapies, and digital health solutions.

The report offers strategic insights across key areas, including segmentation analysis, competitive intelligence, regulatory structures, ESG perspectives and emerging technologies that are reshaping the global women's health therapeutics industry.

Market Leadership in Transition

The women's health therapeutics market is undergoing significant transformation, driven by an aging female population and rising demand for condition-specific treatment options. Companies like Pfizer, Eli Lilly and Novartis AG are actively investing in late-stage R&D for areas such as menopause and postmenopausal osteoporosis ( Chapter 5, Pipeline Assessment and Analysis; Chapter 8, Competitive Landscape ).

The breast cancer segment remains the most dominant, supported by increasing incidence rates and continued innovation in monoclonal antibodies and biosimilars ( Chapter 7, Market Segmentation Analysis ).

Emerging Technologies and Investment Trends

As outlined in Chapter 4 (Emerging Technologies) , cutting-edge innovations such as gene therapy, CRISPR, and transdermal delivery platforms are opening doors for safer, more personalized treatments. These technologies are also enabling commercialization models in digital health and remote care-areas expected to see strong growth.

North America leads regional expansion, projected to grow from $28.4 billion in 2024 to $37.4 billion by 2029 at a 5.6% CAGR ( Chapter 7, Regional Analysis ). This growth is fueled by robust R&D infrastructure, regulatory support and access to biologics and HRT. Meanwhile, Europe and the Asia-Pacific region present significant opportunities as healthcare systems modernize and policies evolve.

Pipeline Assessment and Analysis

Chapter 5 details how companies are diversifying pipelines across hormonal, non-hormonal and biologic therapies aimed at improving efficacy and minimizing side effects.

Roche, in particular, has solidified its leadership in the U.S. market through its strong presence in the breast cancer, postmenopausal osteoporosis, menopause, endometriosis, and PCOS segments. (Chapter 8, Competitive Landscape)

Regulatory and Access Challenges

Chapter 3 (Market Dynamics) highlights persistent barriers such as high treatment costs and slow regulatory pathways, particularly in low-income regions where access to diagnostics and therapies remains limited.

Chapter 6 (Regulatory Structure) explains how regional discrepancies in clinical trial approvals and intellectual property rules impact time-to-market and ROI projections for drug developers.

Strategic Outlook: The Road Ahead

According to Chapter 9 (ESG Perspective) , the industry is increasingly aligning with environmental, social and governance (ESG) goals-focusing on inclusivity in clinical trials, sustainable manufacturing, and broader access to care. Firms integrating ESG into product pipelines and geographic strategies are well-positioned to win both market share and investor confidence.

With rising awareness, policy support and a wave of therapeutic innovation, women's health is becoming central to the future of equitable, personalized healthcare. The next five years will be critical for companies to lead, adapt and innovate in this fast-evolving space.

Report Synopsis

Report Metric	Details
Base year considered	2023
Forecast period considered	2024-2029
Base year market size	$58.3 billion
Market size forecast	$81.2 billion
Growth rate	CAGR of 5.7% for the forecast period of 2024-2029
Segments covered	Women's Health Disorders, and Region
Regions covered	North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
Countries covered	U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, Australia, South Korea and China
Market drivers	. Rising geriatric population of women. . Rising awareness of and accessibility to healthcare and advanced therapeutic products. . Advances in personalized medicine. . Emerging markets.

Additional Insights:

• The women's health therapeutics market is expanding rapidly, driven by increasing awareness, technological advancements, and increased attention to under-addressed conditions such as menopause, endometriosis, and polycystic ovary syndrome (PCOS).
• Governments and healthcare organizations around the world are implementing initiatives to enhance access to women's health treatments, including funding programs for maternal care, reproductive health, and breast cancer screening.

Market leaders include:

• AbbVie Inc.
• Amgen Inc.
• Asahi Kasei Corp.
• AstraZeneca
• Bayer AG
• Bristol-Myers Squibb Co.
• Eisai Co. Ltd .
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc .
• Lilly
• Merck & Co. Inc .
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Navigate Uncertainty with Confidence

In times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we're here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape-providing you with the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That's why, for a limited time, we're offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights.

Get your copy of the report directly from BCC Research.

To request more information or complete your purchase, connect with us at [email protected] .

About BCC Research

BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.

Contact Us

Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA

Email: [email protected]

Phone: +1 781-489-7301

For media inquiries, email [email protected] or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo -

SOURCE BCC Research LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN08052025003732001241ID1109525377